Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Microba Life Sciences Partner on Human Gut Microbiome Research

NEW YORK – Illumina and Australia's Microba Life Sciences said on Monday they will partner on human gut microbiome research in the Asia Pacific region.

The partners will work together on research connecting the microbiome to aspects of human health, including neurological disorders like Parkinson's disease, mental health, sleep, and nutrition.

"With genomic sequencing at the forefront of understanding human health, the partnership will aim to explore and demonstrate potential applications of gut microbiome profiling by combining Illumina's established credibility and global reach in next-generation sequencing with Microba's progressive analytical services," Gretchen Weightman, Illumina's VP and general manager of Asia Pacific and Japan, said in a statement.

Financial and other details of the partnership were not disclosed.

Brisbane, Australia-based Microba offers a proprietary microbiome analysis platform, ranging from a validated sample collection method to bioinformatics.

Illumina has previously boosted several microbiome-focused startups through its Illumina Accelerator program, including UK-based Juno Bio and Millbrae, California-based VastBiome.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.